MLYS Stock Analysis: Buy, Sell, or Hold?
MLYS - Mineralys Therapeutics, Inc. Common Stock
$28.38
-0.58 (-2.00%)
▼
5d:
+2.49%
30d:
+17.37%
90d:
+4.45%
BUY
MODERATE Confidence
Analysis Updated: Jul 10, 2026 12:00 AM ET
Earnings: Aug 11, 2026
28d
Smart Money Distribution
None View Scanner →
Strength: 6.9/10
Get Alerted When MLYS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: MLYS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: MLYS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: MLYS is currently trading at $28.38, which is considered extended relative to its 30-day fair value range of $23.84 to $28.50.
Technical Outlook: Technically, MLYS is showing sideways momentum. Immediate support is located at $25.44, while resistance sits at $31.11.
Market Sentiment: MLYS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $49.00 (+72.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MLYS is showing sideways momentum. Immediate support is located at $25.44, while resistance sits at $31.11.
Market Sentiment: MLYS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $49.00 (+72.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$23.84 -
$28.50
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 72.7% below Wall St target ($49.00)
Trading Range Analysis
30-Day Trading Range
$23.84 -
$28.50
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$25.44
Resistance Level
$31.11
Current Trend
Sideways
Technical data as of
Jul 10, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-13.54
Wall Street Target
$49.00
(+72.7%)
Share & Embed Analysis
Last updated: July 13, 2026 9:18 AM ET
Data refreshes hourly during market hours. Next update: 10:18 AM
Data refreshes hourly during market hours. Next update: 10:18 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MLYS showing a specific setup today?
Insider Activity (6 Months)
1
Buys
15
Sells
Net
INSIDERS SELLING
Recent Transactions
David Malcom Rodman
SELL
416 shares
2026-04-17
David Malcom Rodman
SELL
6348 shares
2026-04-15
David Malcom Rodman
SELL
14058 shares
2026-04-13
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 57 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$111 | 58 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 61 BUY |
|
RVMD
Revolution Medicines Inc |
STRONG BUY
12 analysts |
$200 | 65 BUY |
|
ORIC
Oric Pharmaceuticals Inc |
STRONG BUY
12 analysts |
$20 | 63 BUY |
Advanced MLYS Option Strategies
Professional options setups generated by AI based on today's MLYS price and gamma walls.
